Amol Akhade, Consultant Medical Oncologist Hemato Oncologist at Suyog Cancer Clinics, shared on X:
“CRC Screening Face-Off: Stool vs Blood
Not all non-invasive tests are created equal.
Let’s break it down:
CRC Sensitivity
- Cologuard Plus: 95%
- ColoSense: 94%
- Shield (blood): 80–83%
- FIT: 67–91%
Advanced Adenoma Detection (PREVENTION!)
- ColoSense: 46%
- Cologuard: 43%
- FIT: 20–30%
- Shield: 13–16%
High-Grade Dysplasia
- Cologuard: 74%
- FIT: 47%
- Shield: 23%
- ColoSense: Not Available
Specificity
- FIT: 95%
- Shield: 90%
- Cologuard: 91–94%
- ColoSense: 88%
Verdict:
Blood-based cfDNA is convenient but underperforms where it matters – early detection of pre-cancer.
Cologuard and ColoSense are clear leaders in prevention.
If we want to prevent, not just detect, CRC – stool-based testing still beats.”
More posts featuring Amol Akhade.